



Brightseed Launches the World's First Clinically-Validated, Enterprise AI Platform, Built on Over a Decade of Scientific Research

The company's new health sciences innovation platform connects discovery, development, and commercialization to increase innovation success

SOUTH SAN FRANCISCO--March 25, 2026--Brightseed, Inc., the AI-native life sciences company, today announced the launch of its innovation platform — the first continuous, AI-powered health sciences innovation platform designed to increase the probability of commercial success across health and life sciences.

With this launch, Brightseed formally evolves from a discovery-focused bioactives company into a platform-based enterprise AI company delivering data-as-a-service (DaaS) to global health science organizations. The business evolution is built on the technology and learnings that has allowed Brightseed to produce the first clinically-validated, AI discovered compounds in the commercial market.

Across health and life sciences, more than 75% of early product ideas fail to reach market due to fragmented workflows, disconnected data, and late-stage risk discovery. Innovation has historically been structured as episodic project work rather than a connected, compounding capability.

Brightseed's innovation platform rebuilds that model from the ground up. It connects discovery, development, and commercialization within a unified architecture that preserves scientific insight, evidence, and decision context across the innovation lifecycle — transforming innovation from a gamble into a strategic growth engine.

At its core is Forager™, Brightseed's AI-powered discovery engine built on the world's largest proprietary bioactive dataset spanning more than 11 million natural compounds across 23 health territories. Unlike general-purpose AI systems trained on public data, Brightseed's platform is grounded in proprietary biological intelligence designed specifically for scientific rigor, traceability, and defensibility.



“Health innovation has operated on a broken probability curve for decades,” said Lee Chae, PhD, Co-Founder and Chief Executive Officer of Brightseed. “We built our innovation platform to fundamentally change that curve. By converging deep biological insight, proprietary multi-omics datasets, and cutting-edge AI and machine learning architecture into a continuous innovation foundation, we are defining a new category — one where AI is not an add-on, but the core operating foundation of life sciences innovation.”

Brightseed enters this phase with more than 40 partnerships across consumer health, nutrition, personal care, pharmaceuticals, and animal health, and is transitioning customers to a recurring subscription model aligned with its platform strategy. The company serves the \$6.8 trillion global wellness market and is expanding its enterprise footprint as it prepares for its next phase of growth.

About Brightseed

Backed by over 40 industry leading partners, Brightseed® exists to empower health science teams with the foundation needed to advance science, develop better products, and ultimately transform health through AI. The Bay Area company brings together biology, the world’s largest proprietary dataset, and over a decade of computational science expertise with a shared commitment to illuminating biology and translating scientific insight into real-world impact. Brightseed’s work is guided by the belief that better health outcomes require clarity, precision, and an integrated approach to innovation.

For more information, visit brightseedbio.com.

Media Contact

Nicki Briggs, MS, RDN
Communications, Brightseed
press@brightseedbio.com